A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

NCT05989542 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: PLB1001

Sponsor

Beijing Pearl Biotechnology Limited Liability Company